Aims To assess the effect of trandolapril (2 mg once daily) and indomethacin (25 mg three times daily), alone and in combination, on renal function and renal functional reserve in hypertensive patients (DBP 95-115 mmHg) requiring regular nonsteroidal anti-inflammatory drugs (NSAIDs). Methods Randomized, double-blind, placebo-controlled, four way crossover design. After 3 weeks treatment renal plasma flow (RPF) and glomerular filtration rate (GFR) were measured using the p-aminohippurate (PAH) and inulin methods. Renal functional reserve was estimated by measuring RPF and GFR at the end of an intravenous infusion of dopamine 2 mg kg −1 and 10% amino acid solution.
Introduction antihypertensive effect ACEI require an intact prostaglandin system, and if this is blocked by an NSAID, their The renin-angiotensin system is one of the mechanisms involved in renal autoregulation. Angiotensin II (AII) elicits antihypertensive effect is attenuated [2] . Due to their effect on renal autoregulation the co-administration of ACEI and a dose dependent reduction in renal blood flow (RBF), and a variable effect upon GFR, such that filtration fraction NSAIDs may also adversely affect renal function [3] . Glomerular filtration rate (GFR) and renal plasma flow increases. AII causes afferent and efferent arteriolar vasoconstriction, but has slightly more effect on the efferent (RPF) in the normal kidney increases in response to a protein load. The greatest increases are obtained with a arteriole. AII stimulates intrarenal production of vasodilator prostaglandins, which in turn, help protect the renal combined infusion of dopamine and amino acids [4] . The difference between the unstimulated GFR and the maximal circulation from the vasoconstrictor effects of AII. ACE inhibitors (ACEI) prevent conversion of angiotensin I (AI) GFR achieved, which can be an increase of 20-40%, is called the renal functional reserve (RFR). The increments to AII, thereby dissociating renal blood flow from glomerular in GFR and RPF are usually parallel such that filtration fraction remains unchanged [5] [6] [7] . The main mechanisms involved in eliciting the RFR are: alteration of tubulo- The present study tested the hypothesis that chronic sampling. Patients passed urine before dosing. Trandolapril, indomethacin or placebo were given orally with simultaneous NSAID treatment would blunt and ACEI would improve renal function at steady state and renal functional reserve i.v. bolus injections of PAH (0.5 g in 2.5 ml ) (aminohippurate sodium, MSD, Rahway, New Jersey, USA) and inulin capacity in hypertensive patients. We therefore studied the interaction between indomethacin and the non-sulphydryl (2.5 g diluted to 30 ml with 0.9% saline) (Inutest, LaevosanGesellschaft, Linz, Austria), followed by a continuous ACEI, trandolapril, on RPF and GFR, and upon functional reserve RPF and GFR, using the p-aminohippurate (PAH) infusion of PAH (19.8 mg min −1 ) and inulin (19.5 mg min −1 ) for 6 h. Overhydration was achieved by drinking and inulin clearance methods [10] .
1 l water during the first hour of the PAH/inulin infusion, and maintained, by drinking a volume of water equivalent Methods to the volume of urine passed at each time point up to 6 h post dose. Two aliquots (20 ml each) of urine collected at Approval for the study was obtained from the Grampian Health Board Ethics Committee. Twenty-three patients (10 each time point were stored at −45°C. Blood (10 ml) was collected into a lithium heparin tube at each time point up male, aged 36-66 years, mean age 53.5 years) were recruited from the Aberdeen Blood Pressure Clinic and gave informed to 6 h after the start of the PAH/inulin infusion. After centrifugation the plasma was stored at −45°C. PAH and written consent. All had hypertension (untreated DBP 95-115 mmHg, mean BP 162.8/103.7 mmHg ) and a inulin samples collected 2, 3 and 4 h after the start of the infusions were used to calculate static RPF and GFR. musculoskeletal disorder requiring regular NSAID treatment. Patients were excluded if they had a serum creatinine
Renal functional reserve was stimulated by infusing dopamine (2 mg kg
, grade III hypertensive retinopathy, cerebrovascular, renovascular or peripheral vascular disease, Letchworth, Herts., UK) and 10% amino acid solution (Vamin 9, Kabi Pharmacia, Milton Keynes, UK) for 2 h. ischaemic heart disease, active peptic ulceration, asthma, significant hepatic dysfunction, diabetes mellitus, known
The dopamine/amino acids infusion started 4 h after commencing the PAH/inulin infusion. Plasma and urine intolerance of ACEI or indomethacin, or were women of childbearing potential.
samples were collected 5, 5.5 and 6 h post dose for measurement of PAH and inulin levels from which RPF All patients discontinued NSAID and antihypertensive therapy 3 weeks prior to randomization. Paracetamol up to and GFR were calculated. A colorimetric method was used to determine PAH and inulin concentrations [11] . 4 g day −1 was substituted as an analgesic to control their symptoms. There was a 3 week single-blind run-in period Both RPF and GFR were corrected for body surface to 1.73 m 2 . RPF and GFR were calculated from the mean of during which patients took no antihypertensive treatment but took placebo and paracetamol as required. If patients the 2, 3 and 4 h time points. The mean and peak functional reserve RPF and GFR were calculated from the 5, 5.5 and remained hypertensive (untreated diastolic blood pressure (DBP) 95-115 mmHg ) they proceeded to the double-6 h time points. Filtration fraction (FF) was calculated as a ratio of GFR5RPF for baseline and mean functional reserve blind phase. Patients were withdrawn from the study if their systolic blood pressure (SBP)>180 mmHg, or renal function for each treatment. Analysis of variance suitable for crossover design (SAS, Version 6.08 for Windows) DBP>115 mmHg, or if their musculoskeletal symptoms were inadequately controlled with paracetamol. The study was used to evaluate any change in RPF and GFR and renal functional reserve during the four treatment periods. was a double-blind, placebo-controlled, randomized, four way crossover design. The four treatments were:
The study was designed with 80% power to detect a 90 ml min −1 difference in RPF and a 20 ml min −1 differ-(1) trandolapril 2 mg once daily and indomethacin 25 mg three times daily in combination ( plus paracetamol as required), ence in GFR between treatments at the 5% significance level. (2) trandolapril 2 mg once daily plus placebo ( plus paracetamol as required), Results (3) indomethacin 25 mg three times daily plus placebo ( plus paracetamol as required), Twenty-three eligible patients were recruited to the study. Six patients withdrew from the study after randomization (4) placebo and placebo ( plus paracetamol as required). Each week serum creatinine levels were measured. At the due to; patients request (2), increased symptoms on withdrawal of NSAID (2), DBP>115 mmHg (1) and failure end of each 3 week treatment period renal plasma flow (RPF) and glomerular filtration rate (GFR) were measured to attend unit (1). At recruitment four patients were newly diagnosed hypertensives, seven patients were taking one and using the p-aminohippurate (PAH) and inulin clearance methods [10] . Renal functional reserve was measured at the six were taking two antihypertensive drugs. Bendrofluazide (7) and calcium antagonists (5) were the drugs most end of the PAH and inulin clearance methods during a 2 h i.v. infusion of dopamine (2 mg kg −1 ) and 10% amino acid commonly used. All patients required an NSAID, the most common being ibuprofen (3), sulindac (3) and azapropazone solution [4] . Salt intake was not restricted during the study.
(3). The commonest indications for NSAID treatment were osteoarthritis (10) and gout (4). Other indications were placebo, 559.6 ml min −1 (95% CI 370.6, 748.5) on trandolapril and placebo, 409.3 ml min −1 (95% CI 249.3, 569.4) on rheumatoid arthritis (1), deQuervain's tenosynovitis (1) and ankylosing spondylitis (1) . The present analyses are based on indomethacin and placebo, and 560.4 ml min −1 (95% CI 409.9, 711.0) on trandolapril and indomethacin. There was the 17 patients (7 male) who completed the study. Renal functional reserve was not measured in four patients, either no significant interaction between trandolapril and indomethacin (P=0.53). Neither trandolapril (P=0.83) nor indodue to headache and nausea during dopamine/amino acid infusion (2), or voluntary withdrawal from this part of the methacin (P=0.31) had any significant effect on RPF.
There was no significant difference in functional reserve study (2 There was no significant difference in GFR between treatments: −1.01 ml min −1 (95% CI −7.45, 5.42) for
Renal plasma flow, glomerular filtration rate and filtration fraction placebo and trandolapril, −7.88 ml min −1 (95% CI −15.08, −0.68) for placebo and indomethacin, and −0.36 ml min
All data are presented in Table 1 . Figures 1 and 2 show RPF and GFR respectively at each time point up to 6 h (95% CI −7.58, 6.86) for placebo and trandolapril with indomethacin. post dose.
Renal plasma flow was 309.2 ml min −1 (95% CI 246.8, During dopamine/amino acid infusion, GFR rose to 95.5 ml min −1 (95% CI 78.8, 112.3) on placebo and 371.5) on placebo and placebo, 338.24 ml min There was no significant difference in functional reserve There was no significant difference in RPF between treatments: −22.79 ml min −1 (95% CI −54.82, 9.24) for GFR between treatments: 5.13 ml min −1 (95% CI −4.97, 15.23) for placebo and trandolapril, 6.31 ml min −1 (95% CI placebo and trandolapril, −10.37 ml min −1 (95% CI −30.7, 9.96) for placebo and indomethacin, −14.78 ml min Cottone et al. studied younger (mean age 40 years) patients with newly diagnosed hypertension, who may respond Hypertension and musculoskeletal disorders commonly coexist, and with increasing use of ACEI in the treatment differently to dopamine/amino acid stimulation than the older (mean age 53.5 years) patients with established of hypertension, NSAIDs and ACEI may be co-prescribed. This study compared the effect of trandolapril alone and in hypertension in the present study. Tack et al.
[16] evaluated renal functional reserve in renal transplant recipients and combination with indomethacin on RPF and GFR, and functional reserve RPF and GFR in a group of hypertensive found that hypertensive patients had a greater increase in RFR than normotensive patients (23±10 vs patients who had an indication for chronic NSAID use.
